Assessment of Adding Fenofibrate to Simvastatin on Exercise Test Findings in Patients with Dyslipidemia and Coronary Artery Disease
Introduction : Cardiac events due to coronary artery disease (CAD) are the most common cause of death in all over the world. Myocardial ischemia and its consequent heart failure are considered as common problems and complications of CAD. The purpose of this study was to assess the anti-ischemic effe...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | fas |
| Published: |
Ardabil University of Medical Sciences
2013-12-01
|
| Series: | Journal of Ardabil University of Medical Sciences |
| Subjects: | |
| Online Access: | http://jarums.arums.ac.ir/browse.php?a_code=A-10-27-7&slc_lang=en&sid=1 |
| _version_ | 1818415672702533632 |
|---|---|
| author | Reza Karbasi Afshar Ayat Shahmari Eiman Lotfian Amin Saburi |
| author_facet | Reza Karbasi Afshar Ayat Shahmari Eiman Lotfian Amin Saburi |
| author_sort | Reza Karbasi Afshar |
| collection | DOAJ |
| description | Introduction : Cardiac events due to coronary artery disease (CAD) are the most common cause of death in all over the world. Myocardial ischemia and its consequent heart failure are considered as common problems and complications of CAD. The purpose of this study was to assess the anti-ischemic effects of fibrates in patients with CAD. Methods : This clinical-trial study was conducted on patients with dyslipidemia and CAD referred to the Baqiyatallah university hospital, Tehran, during 2008-2010. A total of 124 patients randomly divided into two groups: the first group (64 patients) received simvastatin (20-60 mg/day)+fenofibrate (200 mg/day) with lipid-limited diet and exercise and the second group (60 patients) received simvastatin (20-60 mg/day) with diet and exercise for one year and the patients were evaluated at the end of this period. Results : The mean age was 54.3±6.5 years and 53.2% of patients were male. Metabolic equation index was changed from 4.32±0.5 to 5.68±0.5 at the first group (P<0.001) and 4.43±0.9 to 4.41±1.1 at the other one (P=0.121) and also time of exercise was changed from 5.21±1.81 to 6.01±1.8 (P<0.001) and 5.43±1.26±5.23±1.2 (P=0.089) respectively. No serious adverse effects were seen. Conclusion : Lipid-lowering therapy with simvastatin and fenofibrate reduces myocardial ischemia. Therefore it’s recommended to add fenofibrate to statinsin the treatment of dyslipidemia in patients with high risk of cardiovascular accidents as complementary treatment. |
| first_indexed | 2024-12-14T11:38:43Z |
| format | Article |
| id | doaj.art-8047b9d9d9b34082ac71d5a03306ee8b |
| institution | Directory Open Access Journal |
| issn | 2228-7280 2228-7299 |
| language | fas |
| last_indexed | 2024-12-14T11:38:43Z |
| publishDate | 2013-12-01 |
| publisher | Ardabil University of Medical Sciences |
| record_format | Article |
| series | Journal of Ardabil University of Medical Sciences |
| spelling | doaj.art-8047b9d9d9b34082ac71d5a03306ee8b2022-12-21T23:02:55ZfasArdabil University of Medical SciencesJournal of Ardabil University of Medical Sciences2228-72802228-72992013-12-01134406412Assessment of Adding Fenofibrate to Simvastatin on Exercise Test Findings in Patients with Dyslipidemia and Coronary Artery DiseaseReza Karbasi Afshar0Ayat Shahmari1Eiman Lotfian2Amin Saburi3 Introduction : Cardiac events due to coronary artery disease (CAD) are the most common cause of death in all over the world. Myocardial ischemia and its consequent heart failure are considered as common problems and complications of CAD. The purpose of this study was to assess the anti-ischemic effects of fibrates in patients with CAD. Methods : This clinical-trial study was conducted on patients with dyslipidemia and CAD referred to the Baqiyatallah university hospital, Tehran, during 2008-2010. A total of 124 patients randomly divided into two groups: the first group (64 patients) received simvastatin (20-60 mg/day)+fenofibrate (200 mg/day) with lipid-limited diet and exercise and the second group (60 patients) received simvastatin (20-60 mg/day) with diet and exercise for one year and the patients were evaluated at the end of this period. Results : The mean age was 54.3±6.5 years and 53.2% of patients were male. Metabolic equation index was changed from 4.32±0.5 to 5.68±0.5 at the first group (P<0.001) and 4.43±0.9 to 4.41±1.1 at the other one (P=0.121) and also time of exercise was changed from 5.21±1.81 to 6.01±1.8 (P<0.001) and 5.43±1.26±5.23±1.2 (P=0.089) respectively. No serious adverse effects were seen. Conclusion : Lipid-lowering therapy with simvastatin and fenofibrate reduces myocardial ischemia. Therefore it’s recommended to add fenofibrate to statinsin the treatment of dyslipidemia in patients with high risk of cardiovascular accidents as complementary treatment.http://jarums.arums.ac.ir/browse.php?a_code=A-10-27-7&slc_lang=en&sid=1CAD; Dyslipidemia; Exercise Test; Simvastatin; Fenofibrate |
| spellingShingle | Reza Karbasi Afshar Ayat Shahmari Eiman Lotfian Amin Saburi Assessment of Adding Fenofibrate to Simvastatin on Exercise Test Findings in Patients with Dyslipidemia and Coronary Artery Disease Journal of Ardabil University of Medical Sciences CAD; Dyslipidemia; Exercise Test; Simvastatin; Fenofibrate |
| title | Assessment of Adding Fenofibrate to Simvastatin on Exercise Test Findings in Patients with Dyslipidemia and Coronary Artery Disease |
| title_full | Assessment of Adding Fenofibrate to Simvastatin on Exercise Test Findings in Patients with Dyslipidemia and Coronary Artery Disease |
| title_fullStr | Assessment of Adding Fenofibrate to Simvastatin on Exercise Test Findings in Patients with Dyslipidemia and Coronary Artery Disease |
| title_full_unstemmed | Assessment of Adding Fenofibrate to Simvastatin on Exercise Test Findings in Patients with Dyslipidemia and Coronary Artery Disease |
| title_short | Assessment of Adding Fenofibrate to Simvastatin on Exercise Test Findings in Patients with Dyslipidemia and Coronary Artery Disease |
| title_sort | assessment of adding fenofibrate to simvastatin on exercise test findings in patients with dyslipidemia and coronary artery disease |
| topic | CAD; Dyslipidemia; Exercise Test; Simvastatin; Fenofibrate |
| url | http://jarums.arums.ac.ir/browse.php?a_code=A-10-27-7&slc_lang=en&sid=1 |
| work_keys_str_mv | AT rezakarbasiafshar assessmentofaddingfenofibratetosimvastatinonexercisetestfindingsinpatientswithdyslipidemiaandcoronaryarterydisease AT ayatshahmari assessmentofaddingfenofibratetosimvastatinonexercisetestfindingsinpatientswithdyslipidemiaandcoronaryarterydisease AT eimanlotfian assessmentofaddingfenofibratetosimvastatinonexercisetestfindingsinpatientswithdyslipidemiaandcoronaryarterydisease AT aminsaburi assessmentofaddingfenofibratetosimvastatinonexercisetestfindingsinpatientswithdyslipidemiaandcoronaryarterydisease |